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Abstract 
 
 
Ferrocene based chalcones [(η5-C5H4)2Fe {COCH=CHC6H5}] were prepared from the reaction 
of 1,1’- Diacetylferrocene with Benzaldehyde.  The ferrocenyl pyrazolines are synthesized from 
the reaction of  [(η5-C5H4)2Fe {COCH=CHC6H5}]  and  Hydrazine Hydrate and Phenyl 
Hydrazine . Characterization of these organometallic compounds was carried out using FTIR and 
1
HNMR.  The results indicate that these compounds are successfully formed and can be explored 
in future research work especially as biologically active agents and molecular sensors . 
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CHAPTER - 1 
INTRODUCTION 
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1.1 Ferrocene 
Ferrocene or di(η5-cyclopentadienyl) iron(II) was accidentally discovered by Peter L. 
Pauson and his graduate student Tom Kealy in 1951 when they attempted the reductive coupling 
of the Grignard reagent cyclopentadienyl magnesium bromide in the presence of ferric 
chloride
[1]
.  The unique sandwich structure of ferrocene was first predicted by infrared and 
nuclear magnetic resonance spectroscopies and later confirmed by X-ray crystallography in 
1954
[1].
 
According to the literature survey in 1954, ferrocene comprises a ferrous ion (Fe
2+
) 
coordinated to two cyclopentadienyl (Cp) rings.  The d orbitals on Fe
2+
 are coordinated into the π 
orbitals on the two cyclopentadienyl radicals to form a unique sandwich structure.  It was stable 
to high temperatures and unaffected by water, strong acids and alkalis.  The unique stability of 
ferrocene is attributed to the distribution of 18 π electrons in the e B2gB and a B1gB non 
bonding molecular orbitals (Fig. 1). 
Ferrocene behaves like an aromatic compound.  It is susceptible to direct electrophilic 
substitution reactions, giving rise to a variety of substituted ferrocenes.  Ferrocene has provided a 
very rich chemistry as a super aromatic compound and had led to multiple applications in the 
field of materials and molecular engineering, molecular ferromagnets
 [ 2]
, modified electrodes for 
redox catalysis (titration of glucose in blood), polymers and dendritic electrochemical sensors for 
molecular recognition and antitumor drugs due to its interesting redox properties.  At room 
temperature ferrocene is an air stable orange colored solid and it can be oxidized to blue-green 
ferrocenium cation, [(C5H5)2Fe]
+
.  The inter-ring spacing in ferrocene is 332 pm and the distance 
between the Fe—C bond is 204 pm.  The inter-ring spacing in ferrocene is 332 pm and the 
distance between the Fe—C bond is 204 pm.  Ferrocene at room temperature crystallizes in a 
monoclinic form, at T<164K in a triclinic form and in an orthorhombic modification at T<110K.  
In the monoclinic form disorder phenomena feign a staggered conformation (D5d) of individual 
sandwich molecules.  In the triclinic form, the molecules deviate from the eclipsed conformation 
(D5d) by 9° while in the orthorhombic form the rings are fully eclipsed (D5h).  In the gas phase 
ferrocene also adopts an eclipsed conformation, the rotational barrier being small. 
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Fig 1 
Ferrocene can act as a one electron donor undergoing oxidation to the ferrocenium ion.  This has 
led to the use of ferrocene as a model for sensors and non-linear optical materials
[2]
.  Compared 
to other metallocenes, ferrocene is more widely employed in drug design.  This is prompted by 
several factors, foremost of which is the reputation of ferrocene as a ―safe‖ metallocene. Acute 
and chronic tests of ferrocene and several of its derivatives attested to the relative safety of these 
compounds in many mammalian species (dogs, rats, mice, monkeys)
[3,4,5].
 
1.2 Medicinal chemistry of ferrocene 
Medicinal chemists are also open to the inclusion of ferrocene into their drug design 
strategies because of the novelty introduced by its presence.  Ferrocene is a stable, nontoxic 
compound and haveing good redox properties.  Now research is going on to design  new 
compounds which are active against a wide range of cancers and have lesser side effects.  
Ferrocenes are also known to exhibit a wide range of biological activity and also ferrocene has 
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attracted special attention since it is a neutral chemically stable and non-toxic molecule.  Many 
ferrocenyl compounds display interesting, cytotoxic, antitumor, antimalarial, anti-fungal and 
DNA cleaving activities.  There are many examples in the literature citing the use of ferrocene in 
drug design strategies.  In one study on some non-steroidal anti-inflammatory agents, the 
replacement of the aromatic ring by ferrocene did not improve anti-arthritic or platelet 
aggregatory activities in the resulting compounds
[6].
  Investigations with ferrocene-containing 
penicillins, cephalosporins and rifamycins showed that the inclusion of ferrocene did not confer 
any special advantage
 [7, 8].
 On the other hand, significant changes in activity profiles had been 
recorded when ferrocene was introduced into established drugs like tamoxifen and chloroquine. 
Ferrocenyl derivatives are among the most potential compounds which can be used in 
cancer research.  Cancer is a class of disease characterized by uncontrolled cell proliferation and 
the ability of these cells to invade other tissues.  Cancer can be treated by several methods 
including chemotherapy, which is one of the main weapons in the fight of cancer.  
Chemotherapy is the treatment of cancer with drugs (anticancer drugs) that destroy the cancerous 
cells.  In the last decade a revolution in the cancer treatment has been enacted by the 
organometallic chemists.  Many ferrocenyl derivatives show good results as antitumor agents 
and some of them are now in clinical trials.  Ferrocifens are the first molecules shown to be 
active against both hormone dependent and hormone independent breast cancer cells. 
 
OH
OCH2CH2N(CH3)2
H3CH2C
OH
OCH2CH2N(CH3)2
H3CH2C
Fe
 
Fig.2 (a) Ferrocenyl derivative of tamoxifen                        Fig.2 (b) Tamoxifen 
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Ferrocene containing compounds has recently been reported to have antitumor activity due to 
metabolic formation of ferrocenium ions.   Water soluble ferrocenyl derivatives can also be used 
as anti-cancer agents
 [9-10]
 ( Figure-3a,3b).  These compounds are more potent as an anticancer 
drug than water insoluble molecule. 
 
Fig.3a & 3b: Water soluble ferrocenyl derivatives as anti cancer agent. 
Some examples of the most important ferrocenyl compounds that have a good activity as 
anti cancer agents are ferrocenium tetrafluoroborate salt
[11] 
and ferrocenium iodate 
[12]
 as shown 
in Fig 4(a) & Fig 4(b). 
 
Fig.4(a):Ferrocenium tetrafluoro borate salt 
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Fig.4(b) Ferrocenium tri iodate 
1.3. Ferrocenyl derivatives 
1.3.1 Ferrocenyl chalcones 
 Chalcones are a family of aromatic ketones with two aromatic groups bridged by an 
enone linkage (Ar–COCH=CH–Ar’) [13].  The term chalcone is given to the 1,3-diphenylprop-2-
en-1-one framework. Chalcones occur in nature as precursors of flavonoids.  They are also 
readily synthesized in the laboratory and structural modifications of the chalcone template are 
readily achieved.  The biological activities of chalcones are equally wide ranging
[14,15].
  Not 
many structural templates can claim association with such diverse pharmacological activities, of 
which cytotoxicity, anti-tumors, anti inflammatory, antiplasmodial, antileishmanial, antioxidant, 
immunosuppression are some examples.  In this regard, chalcones can be regarded as a 
privileged structure, a term used to describe selected structural motifs capable of binding to 
multiple, unrelated classes of receptors or enzymes with high affinity
 [16] .  
They have a wide 
range of applications covering from materials with various biological activities 
[17–20]
 to non-
linear optical (NLO) 
[21–24]
 and electroactive fluorescent 
[25,26]
 materials .The synthesis of 
chalcones is generally able to be achieved by base-catalyzed aldol condensation 
[27]
.  Ferrocenyl 
chalcones belong to a chalcone family in which one aromatic group (Ar or Ar’) is substituted by 
the ferrocenyl group. 
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Fig.5
 
 Dong-Young Noh in 2009 reported some ferrocenyl chalcones which are designed to 
modulate the electrochemical and optical properties of the polycyclic moieties by the electron 
donating ferrocenyl group through the enone linkage.  They show antimalarial activity due to 
lipophillicity, electronic effects and size of the ferrocene ring associated with the chalcone. 
Recently a series of ferrocenyl chalcones linked with aromatic and polycyclic compounds such 
as ferrocene,
[28]
 naphthalene
[29]
 and anthracene (Fig. 6a & 6b).
[30]
  are studied because these 
systems were designed in order to modulate the electrochemical and optical properties of the 
polycyclic moieties by the electron donating ferrocenyl group through the enone linkage. The 
optical properties of the naphthalene and anthracene moieties were quenched by the ferrocenyl 
moiety which acts as a quencher. 
 
 
                        Fig 6(a)                                                                                Fig 6(b) 
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                              Fig 7(a)                                                                    Fig 7(b) 
 
Some ferrocenyl derivative have been reported to show interesting electrochemical and 
spectroscopic properties ( Fig. 7a & 7b).
[31,32]
 
 
Scheme-1 
Scheme 1 shows the reaction to prepare ferroquine which shows antiplasmodial and other 
biological properties.
[33]
 
1.3.2  Ferrocenyl pyrazolines and pyrazolos 
 Heterocyclic compounds are cyclic organic substances which contain in the ring system 
at least one atom other than carbon.  It seems likely that more than a third of the known organic 
compounds are heterocyclic.  Many alkaloids, vitamins, antibiotics and many synthetic 
medicines and dyestuffs are heterocyclic, and also are many nucleic acids which are most 
intimately connected with the processes of life.  Any atom which can form two covalent bonds is 
capable forming a heterocyclic compound.  All the known heterocyclic compounds involve an 
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element from group IVB, VB or group VIB of the periodic table.  The most important 
―heteroatoms‖ are nitrogen, oxygen and sulfur. 
Any of the group of heterocyclic compounds containing three carbon atoms , two 
adjacent nitrogen atoms and one double bond in the ring known as pyrazolines. Considerable 
attention has been focused on pyrazoline derivatives due to their interesting biological activities. 
They have found to possess a Antifungal
[34],
 antibacterial
[35],
 antidepressant
[36],
 
anticonvulsant
[37,38]
 anti-inflammatory
[39]
 , anti-tumor
[40]
 , antidiabetic, anaesthetic and 
analgesic
[41-43]
.  Pyrazolines and their derivatives have been found to possess antihypertensive
 [44]
 
antioxidant 
[45]
 and anticancer
[46,47]
 activities.  Recently Ali et al., have reported 1,3,5-
trisubstituted pyrazolines for anti HIV activity involving one additional methyl group on ring A 
and isoniotinyl group at 1 position of pyrazolyl ring
[48]. 
 
Fig 8 
Similar to pyrazoline, another heterocyclic compound, pyrazole also shows interesting 
biological properties.  Pyrazole was described for the first time by Buchner, who obtained it by 
decarboxylation of pyrazole-3,4,5-tricarboxylic acid in 1889 (Scheme 2) 
[49]
. 
N
N
H
COOH
HOOC
HOOC
HEAT
N
N
H
+ 3CO2
 
Scheme-2 
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Some pyrazole compounds like 3-n-nonypyrazole and levo-β-(1-pyrazolyl)alanine are the 
naturally occuring pyrazole derivative ( Fig. 10).  This pyrazolic amino acid has been isolated 
from watermelon seeds
.[50]
 . 
N
N
H
(CH2)8CH3
N
N
CH2CH(NH2)COOH  
Fig 10. 
Combination of a ferrocenyl moiety with heterocyclic structures may increase their 
biological activities or create new medicinal properties.  Ferrocene containing pyrazolo quinoline 
derivatives that may have significant biological activities.  The wide range of biological activities 
of pyrazoles has made them popular synthetic targets.  Some of the pyrazole derivatives which 
are used as reverse transcriptase inhibiters for HIV disorders and can also be useful for the 
treatment of Alzheimer’s disease (Fig. 11a & 11b). 
N
N N
R
Fe
Fe
NO2
N
N
OH
 
Fig 11(a)                                                Fig 11(b) 
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2.1. Introduction 
Much of the basic information obtained about the chemistry of the pyrazole moiety was 
its aromatic properties compared to those of benzene derivatives.  The first natural pyrazole 
derivative was isolated by Japanese workers in 1954 who isolated 3-n-nonypyrazole from 
Houttuynia Cordata which is a plant of the ―piperaceae‖ family from tropical Asia.  They 
observed the antimicrobal activity of that compound.  Another naturally occuring pyrazole 
derivative is levo-β-(1-pyrazolyl) alanine.  This pyrazolic amino acid has been isolated from 
watermelon seeds (Citrullus Vulgaris).  These are the only naturally occuring pyrazole 
derivatives known at present 
[50].
 
 There are many methods to synthesize the pyrazole derivatives.  Due the wide range of 
biological activities of pyrazoles has became popular for synthetic targets.  The synthesis of 
pyrazole derivatives from β-dicarbonyl compounds and hydrazines is the most widely used and 
the most general method for pyrazole synthesis ( Scheme 3) 
[50].
  
 
H3C
C
C
C
ONa
O
H
H
H3CHN-NH2
N
CH3
N
CH3
N
N
CH3
+
 
Scheme-3:  
An alternative strategy to employ masked 1,3-dicarbonyl compounds such as β-aminoenones has 
been described by Gonzalez-Ortega and co-workers  and also by Dominguez et al  β-
aminoenones react with hydrazine derivatives to afford regioselectively 1,3,5-trisubstituted 
pyrazoles as shown in scheme 4 
[51,52,53]
.
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R
CH3
NH2O
+ H2N-NHR*
N
N
CH3
R*
R
+
N
N
R
H3C
R*  
Scheme-4 
  
Pyrazoline are prominent nitrogen containing heterocyclic compounds play important role in 
medicinal chemistry.  Considerable attention has been focused on pyrazoline derivatives due to 
their interesting biological activities.  Biological activities of pyrazoline prompted to synthesize 
various substituted pyrazoline derivatives.  Synthesis of novel isoxazoline derivative (scheme-5) 
remains a main focus of medicinal chemist, due to their diverse pharmacological activity
 [50].
 
R
OCH3
O
Pyridin
NH2  NH2 HCl
Reflux
OCH3
R HX
HA
HB
Scheme 5
 
 Pyrazoles are known not only as potent insecticides, herbicides, and monomers for the 
preparation of electroluminiscent and thermo resistant materials, but also as antitumor, anti-
inflammatory, antimicrobial, antipsychotic, or analgesic agents. Incorporation of pyrazole 
pharmacophore into the ferrocene scaffold should have an attracting structural result for 
development of novel antitumor agent.A series of bis(trifluoromethyl) pyrazoles (BTPs)  has 
been found to be a novel inhibitor of cytokine production. The pyrazole derivatives plays an 
important role in the regulation of renal vascular and tubular functions and contributes to the 
control of arterial blood pressure. . It is also produced in the brain, where it regulates vascular 
tone and contributes to the regulation of the cerebral blood flow 
[50].
 The last example to 
biologically active pyrazole derivative is Fipronil . Fipronil is the most important example of the 
phenylpyrazole or fiprole insecticides. It is a major insecticide acting as a non-competitive 
blocker of the γ-aminobutyric acid (GABA) receptor/chloride channel [51]. 
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2.2. Results and Discussions 
1,1’-Diactylferrocene (1) was prepared by taking ferrocene, acetyl chloride and 
anhydrous AlCl3 in 1:1:2 ratios respectively (Scheme 6).  The IR of compounds 1 shows peaks at 
1656 cm
-1 is indicative of its carbonyl group due to νC=O stretching vibration.  
  
 
 
 
Scheme 6 
The ferrocenyl dichalcone, 2 was synthesized by room temperature stirring reaction of 
diacetyl ferrocene and benzaldehyde at 1:6 ratio (scheme-7).  The infra-red spectra (Fig.12) of 2 
shows the presence of peak at 1656 cm
-1
,  due to the νC=O group of the ferrocenyl moiety and the 
peak at 1598 cm
-1
, due to the  νC=C  of the aromatic region.  The proton NMR spectroscopy 
(Fig.13) of 2 shows two singlet at  5.081 and  4.682, each corresponding to four protons of the 
cyclopentadiene ring. Peaks at 7.42-7.82ppm (multiplet) corresponds to five protons of the 
benzene ring.  Two doublets at  7.62 and  7.36 corresponding to the two olefinic protons 
respectively. 
 
 
  
 
 
 
Scheme 7 
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2
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Room temperature reaction of ferrocenyl dichalcone with hydrazine hydrate for 3 hours 
results in the formation of orange product as shown in the (scheme-8).  The orange compound 
was isolated and FTIR was performed.  Scheme 8 shows the tentative structure of the compound.  
The IR of compounds 3 shows peaks at 1652 cm
-1 
is indicative of its carbonyl group due to( 
νC=O) stretching vibration.  The peak at 2921 cm
-1  
shows due to the ( νN-H ) stretching vibration 
and the peak at 2357 cm
-1  
shows due to the  (νC=O) stretching vibration. 
  
 
 
 
 
 
 
 
Scheme 8 
 
Ferrocenyl dichalcone was also reacted with phenyl hydrazine at reflux temperature to obtain orange 
coloured product as shown in the (scheme-9).  Tentative structure has been predicted from the 
preliminary observation.  
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Scheme 9 
 
 2.3. Experimental Section 
2.3.1. General Procedures 
 All reactions were performed under nitrogen atmosphere and room temperature.  
Solvents were purified and distilled prior to use.  FT-IR spectra as KBr pellets of the samples 
were recorded on a perkin elmer VX-II spectrometer. NMR spectra was recorded in a 400 MHz  
bruker NMR instrument in CDCl3 solvent.  Ferrocene was procured from Spectrochem and used 
without purification.  
2.3.2. Preparation of 1,1’- diacetyl ferrocene (1) 
A 100 ml two necked flask equipped with glass stoppers, magnetic stirring bar was 
connected with a schlenk line manifold. To this flask 2 g (0.01 moles) of ferrocene was added 
and then to it 25 ml of CH2Cl2 was poured.  To the stirring solution of ferrocene 2.5 ml (0.03 
moles) of acetyl chloride was added drop wise with a syringe.  The stirred reaction mixture was 
cooled in the ice bath for 15 minutes and then 4.1 g (0.03 moles) of anhydrous AlCl3 was added 
C
C
H2
CH
NN
Fe
H
N
H2N
Fe
C
C
H
O
H
C
C
H
C
O
C
H
C
H2
C
CH
N
N
+
reflux,8h Ethanol, Acetic acid
2
3
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in small portions during 15 minutes. After the addition the ice bath was removed and the 
reaction mixture was stirred for additional 30 minutes at room temperature.  The color of the 
reaction mixture transformed to dark violet.  The formation of the diacetyl derivative of 
ferrocene was monitored by Thin Layer Chromatography (using CH2Cl2 / hexane in 1:1 ratio).  
The reaction mixture was then poured on 50 g of crashed ice in 50 ml of water in a beaker.  The 
flask was then rinsed with small amount of CH2Cl2 and the combined layers were transferred 
into a separatory funnel.  The organic layer contained the desired product of diacetyl ferrocene, 
[(5-C5H4)2Fe(COCH3)2] and was extracted with CH2Cl2.  The combined organic layers were 
dried to obtain the diacetyl ferrocene for further synthesis.  Purification of the compound was 
done by column chromatography using Pet-ether/dichloromethene as solvent mixture. 
1:IR (CH2Cl2,cm
-1
): 1656 (s) 
 
2.3.3. Synthesis of 1,1’-Fc(COCH=CHPh)2 (2) 
To the round bottom flask 0.270 gmof diacetyl ferrocene was dissolved in 5ml. ethanol.  
Then it was stirred for 15mins.  Then 0.04gm of NaOH was added.After 20mins.0.636gm of 
Benzaldehyde with 2ml.ethanol was added in 1:6 ratio.  Then the stirring was continued for 3-4 
hrs. at room temperature. The color of the reaction mixture transformed orangered to dark 
orange.  The formation of the ferrocenyl dichalcone was monitored by Thin Layer 
Chromatography (using hexane and ethyl acetate in 1:1 ratio).   
2: IR:( CH2Cl2,cm
-1
):1656 (s), 1598 (s). 1H NMR(CDCl3, ): 4.68 (4H ,s, C5H4), 5.082 (4H ,s, 
C5H4), 7.428-7.83 (10H , m, Ph-) 7.6 ( 2H ,d, =CH) 7.35 (2H, d, =CH). 
2.3.4. Reaction of Ferrocenyl-dichalcone (2)  with hydrazine hydrate 
 To 100 ml two necked round bottom flask equipped with glass stoppers, magnetic stirring 
bar was connected with a nitrogen cylinder. 0.1mm of diacetyl ferrocene was dissolved in 5ml. 
ethanol.to this flask.  After for 15mins. Of stirring 0.04gm of NaOH was added. To it   After 
20mins.0.636gm of Benzaldehyde with 2ml.ethanol was added in 1:6 ratio.Then stire for 3-4 hrs 
till the deep orange colour precipitate formed.  The product was separated by thin layer 
chromatography.  
3: IR:( KBr,cm-1):1652  (s), 2921 (m, br) 
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 2.3.5 Reaction of Ferrocenyl-dichalcone (2) with Phenyl hydrazine  
A 100 ml two necked flask equipped with glass stoppers, magnetic stirring bar was 
connected with a nitrogen cylinder. To this flask 0.1mm of diacetyl ferrocene was dissolved in 
5ml. ethanol. Then it was stirred for 15mins.Then 0.04gm of NaOH was added. After 20mins 
0.648 Phenyl hydrazine was added followed by  2ml ethanol in1:6 ratio and the stiring was 
continued  for 5-6 hours till the precipitate formed .  Initial colour of the reaction mixture was  
yellowish orange and after stirring the colour changes to red. The product was separated by thin 
layer chromatography followed by pet ether and ethyl acetate in 1:10 ratio.  
4: IR:( KBr,cm-1):1657  (s), 2925 (m, br) 
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Fig.12  : IR spectra of  1,1’- diacetyl ferrocene 
 
 
Fig.13: IR spectra of 1,1 ’-Fc(COCH=CHPh)2 
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Fig.14 :
1H NMR Spectrum of 1,1 ’-Fc(COCH=CHPh)2 
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3 Conclusions 
 Diactylferrocene was successfully used to prepare 1,1’-ferrocenyl dichalcone (2) in high 
yield.  Ferrocenyl-dichalcone has been characterized by FTIR and NMR spectroscopy.  
Ferrocene containing pyrazoline compound (3) has been synthesized by the room temperature 
reaction of ferrocenyl-dichalcone with hydrazine hydrate and preliminary characterization was 
performed by spectroscopic techniques.  Reaction of Ferrocenyl-dichalcone with 
phenylhydrazine at higher temperature results in the formation of the phenyl analogue of 3. 
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